Page 80 - HIV/AIDS Guidelines
P. 80

Table 6. Advantages and Disadvantages of Antiretroviral Components Recommended as
            Initial Antiretroviral Therapy (page 4 of 4)


               ARV        ARV              Advantages                             Disadvantages
               Class    Agent(s)
             Dual-NRTI  ABC/3TC   • Virologic response noninferior to  • Potential for ABC HSR in patients with HLA-B*5701
             pairs (in             ZDV/3TC                        • Increased potential for cardiovascular events, especially in
             alphabetical         • Better CD4 count responses than with  patients with cardiovascular risk factors
             order)                ZDV/3TC                        • Inferior virologic responses in patients with baseline HIV RNA
                                  • Once-daily dosing              >100,000 copies/mL when compared with TDF/FTC in ACTG
                                  • Coformulation                  5202 study; however, this was not seen in the HEAT study.
                                  • No food effect
                                  • No cumulative TAM-mediated resistance
                        TDF/FTC   • Better virologic responses than with  • Potential for renal impairment, including Fanconi syndrome
                                   ZDV/3TC                         and acute renal insufficiency
                                  • Better virologic responses than with  • Early virologic failure of NVP + TDF + (FTC or 3TC) in small
                                   ABC/3TC in patients with baseline HIV  clinical trials
                                   RNA >100,000 copies/mL in ACTG 5202  • Potential for decrease in BMD
                                   study; however, this was not seen in the
                                   HEAT study.
                                  • Active against HBV; recommended dual-
                                   NRTI for HIV/HBV coinfection
                                  • Once-daily dosing
                                  • No food effect
                                  • Coformulated (TDF/FTC, EFV/TDF/FTC,
                                   and RPV/TDF/FTC)
                                  • No cumulative TAM-mediated resistance
                        ZDV/3TC   • Coformulated (ZDV/3TC and     • Bone marrow suppression, especially anemia and neutropenia
                                   ZDV/3TC/ABC)                   • GI intolerance, headache
                                  • No food effect (although better tolerated  • Mitochondrial toxicity, including lipoatrophy, lactic acidosis,
                                   with food)                      hepatic steatosis
                                  • Preferred dual NRTI in pregnant women  • Compared with TDF/FTC, inferior in combination with EFV
                                                                  • Less CD4 increase compared with ABC/3TC
                                                                  • Twice-daily dosing


            Key to Abbreviations: 3TC = lamivudine, ABC = abacavir, APV = amprenavir, ART = antiretroviral therapy, ARV = antiretroviral, ATV = atazanavir,
            ATV/r = atazanavir/ritonavir, AV = atrioventricular, BMD = bone mineral density, CNS = central nervous system, CYP = cytochrome P, d4T = stavudine,
            ddI = didanosine,  DRV/r = darunavir/ritonavir, ECG = electrocardiogram, EFV = efavirenz, FPV = fosamprenavir, FPV/r = fosamprenavir/ ritonavir,
            FTC = emtricitabine, GI = gastrointestinal, HBV = hepatitis B virus, HSR = hypersensitivity reaction, INSTI = integrase strand transfer inhibitor,
            LPV/r = lopinavir/ritonavir, MI = myocardial infarction, msec = milliseconds, MVC = maraviroc, NNRTI = non-nucleoside reverse transcriptase inhibitor,
            NRTI = nucleoside reverse transcriptase inhibitor, NVP = nevirapine, PI = protease inhibitor, PPI = proton pump inhibitor, RAL = raltegravir,
            RPV = rilpivirine, RTV = ritonavir, SJS = Stevens-Johnson syndrome, SQV/r = saquinavir/ritonavir, TAM = thymidine analogue mutation,
            TDF = tenofovir, TEN = toxic epidermal necrosis, ZDV = zidovudine

















            Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents         F-19

                            Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.
   75   76   77   78   79   80   81   82   83   84   85